| US 7,531,544 B2 | ||
| Xanthine phosphodiesterase V inhibitors | ||
| Samuel Chackalamannil, Califon, N.J. (US); Yuguang Wang, Monroe, N.J. (US); Craig D. Boyle, Branchburg, N.J. (US); and Andrew W. Stamford, Chatham Township, N.J. (US) | ||
| Assigned to Schering Corporation, Kenilworth, N.J. (US) | ||
| Filed on Sep. 10, 2007, as Appl. No. 11/852,638. | ||
| Application 10/777849 is a division of application No. 09/940760, filed on Aug. 28, 2001, granted, now 6,821,978. | ||
| Application 11/852638 is a continuation of application No. 10/777849, filed on Feb. 12, 2004, granted, now 7,268,141. | ||
| Claims priority of provisional application 60/233567, filed on Sep. 19, 2000. | ||
| Prior Publication US 2008/0058354 A1, Mar. 06, 2008 | ||
| This patent is subject to a terminal disclaimer. | ||
| Int. Cl. A61K 31/522 (2006.01); A61P 9/12 (2006.01); A61P 15/10 (2006.01); C07D 473/04 (2006.01); C07D 473/06 (2006.01); C07D 473/08 (2006.01) | ||
| U.S. Cl. 514—263.31 [514/263.36] | 3 Claims |
1. A pharmaceutical composition comprising an effective amount of a compound of the formula:
 or a pharmaceutically acceptable salt thereof and an endothelin receptor agonist.
|